APO RESEARCH · REPORT
Peptide Therapeutics
Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another.
Product & engineering
Understand the product.
Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another.
Selected research
Industry Research
Peptide Therapeutics Industry Research Report 2026
Market perspective
Peptides are short chains of amino acid monomers linked by peptide (amide) bonds, the covalent chemical bonds formed when the carboxyl group of one amino acid reacts with the amino group of another.
Global Peptide Therapeutics key players include Sanofi, Novo Nordisk, Takeda, Eli Lilly, Ipsen, etc. Global top five manufacturers hold a share about 65%.
North America is the largest market, with a share about 55%, followed by Europe and Asia-Pacific, both have a share about 40 percent.
Read the full market overview
In terms of product, Injection is the largest segment, with a share about 70%. And in terms of application, the largest application is Cancer, followed by Central Nervous System.
Report Scope
This report quantifies the global Peptide Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Peptide Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Peptide Therapeutics Market by Company
Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
J & J
Peptide Therapeutics Segment by Type
Injection
Oral
Other
Peptide Therapeutics Segment by Application
Cancer
Metabolic Disorders
Central Nervous System
Other
Peptide Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Peptide Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Oral
- Other
Applications
- Cancer
- Metabolic Disorders
- Central Nervous System
- Other
Companies covered
- Sanofi
- Teva
- Novo Nordisk
- Takeda
- Eli Lilly
- AstraZeneca
- Novartis
- AbbVie
- Ipsen
- Ferring
- Merck
- The Medicines
- J & J
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Peptide Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Injection
- 2.2.3 Oral
- 2.2.4 Other
- 2.3 Peptide Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Metabolic Disorders
- 2.3.4 Central Nervous System
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Peptide Therapeutics Breakdown Data by Type
- 3.1 Global Peptide Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Peptide Therapeutics Forecasted Market Size by Type (2027-2032)
4 Peptide Therapeutics Breakdown Data by Application
- 4.1 Global Peptide Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Peptide Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Peptide Therapeutics Market Perspective (2021-2032)
- 5.2 Global Peptide Therapeutics Growth Trends by Region
- 5.2.1 Global Peptide Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Peptide Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Peptide Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Peptide Therapeutics Market Dynamics
- 5.3.1 Peptide Therapeutics Industry Trends
- 5.3.2 Peptide Therapeutics Market Drivers
- 5.3.3 Peptide Therapeutics Market Challenges
- 5.3.4 Peptide Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Peptide Therapeutics Players by Revenue
- 6.1.1 Global Top Peptide Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Peptide Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Peptide Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Peptide Therapeutics Head Office and Area Served
- 6.4 Global Peptide Therapeutics Players, Product Type & Application
- 6.5 Global Peptide Therapeutics Manufacturers Established Date
- 6.6 Global Peptide Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Peptide Therapeutics Market Size (2021-2032)
- 7.2 North America Peptide Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Peptide Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Peptide Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Peptide Therapeutics Market Size (2021-2032)
- 8.2 Europe Peptide Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Peptide Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Peptide Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Peptide Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Peptide Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Peptide Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Peptide Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Peptide Therapeutics Market Size (2021-2032)
- 10.2 South America Peptide Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Peptide Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Peptide Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Peptide Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Peptide Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Peptide Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Peptide Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in Peptide Therapeutics Business (2021-2026)
- 12.1.4 Sanofi Peptide Therapeutics Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Peptide Therapeutics Business (2021-2026)
- 12.2.4 Teva Peptide Therapeutics Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Novo Nordisk
- 12.3.1 Novo Nordisk Company Information
- 12.3.2 Novo Nordisk Business Overview
- 12.3.3 Novo Nordisk Revenue in Peptide Therapeutics Business (2021-2026)
- 12.3.4 Novo Nordisk Peptide Therapeutics Product Portfolio
- 12.3.5 Novo Nordisk Recent Developments
- 12.4 Takeda
- 12.4.1 Takeda Company Information
- 12.4.2 Takeda Business Overview
- 12.4.3 Takeda Revenue in Peptide Therapeutics Business (2021-2026)
- 12.4.4 Takeda Peptide Therapeutics Product Portfolio
- 12.4.5 Takeda Recent Developments
- 12.5 Eli Lilly
- 12.5.1 Eli Lilly Company Information
- 12.5.2 Eli Lilly Business Overview
- 12.5.3 Eli Lilly Revenue in Peptide Therapeutics Business (2021-2026)
- 12.5.4 Eli Lilly Peptide Therapeutics Product Portfolio
- 12.5.5 Eli Lilly Recent Developments
- 12.6 AstraZeneca
- 12.6.1 AstraZeneca Company Information
- 12.6.2 AstraZeneca Business Overview
- 12.6.3 AstraZeneca Revenue in Peptide Therapeutics Business (2021-2026)
- 12.6.4 AstraZeneca Peptide Therapeutics Product Portfolio
- 12.6.5 AstraZeneca Recent Developments
- 12.7 Novartis
- 12.7.1 Novartis Company Information
- 12.7.2 Novartis Business Overview
- 12.7.3 Novartis Revenue in Peptide Therapeutics Business (2021-2026)
- 12.7.4 Novartis Peptide Therapeutics Product Portfolio
- 12.7.5 Novartis Recent Developments
- 12.8 AbbVie
- 12.8.1 AbbVie Company Information
- 12.8.2 AbbVie Business Overview
- 12.8.3 AbbVie Revenue in Peptide Therapeutics Business (2021-2026)
- 12.8.4 AbbVie Peptide Therapeutics Product Portfolio
- 12.8.5 AbbVie Recent Developments
- 12.9 Ipsen
- 12.9.1 Ipsen Company Information
- 12.9.2 Ipsen Business Overview
- 12.9.3 Ipsen Revenue in Peptide Therapeutics Business (2021-2026)
- 12.9.4 Ipsen Peptide Therapeutics Product Portfolio
- 12.9.5 Ipsen Recent Developments
- 12.10 Ferring
- 12.10.1 Ferring Company Information
- 12.10.2 Ferring Business Overview
- 12.10.3 Ferring Revenue in Peptide Therapeutics Business (2021-2026)
- 12.10.4 Ferring Peptide Therapeutics Product Portfolio
- 12.10.5 Ferring Recent Developments
- 12.11 Merck
- 12.11.1 Merck Company Information
- 12.11.2 Merck Business Overview
- 12.11.3 Merck Revenue in Peptide Therapeutics Business (2021-2026)
- 12.11.4 Merck Peptide Therapeutics Product Portfolio
- 12.11.5 Merck Recent Developments
- 12.12 The Medicines
- 12.12.1 The Medicines Company Information
- 12.12.2 The Medicines Business Overview
- 12.12.3 The Medicines Revenue in Peptide Therapeutics Business (2021-2026)
- 12.12.4 The Medicines Peptide Therapeutics Product Portfolio
- 12.12.5 The Medicines Recent Developments
- 12.13 J & J
- 12.13.1 J & J Company Information
- 12.13.2 J & J Business Overview
- 12.13.3 J & J Revenue in Peptide Therapeutics Business (2021-2026)
- 12.13.4 J & J Peptide Therapeutics Product Portfolio
- 12.13.5 J & J Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst